Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 631-640

  Shen, Sining ^a,c   Yue, Han ^b   Li, Yin ^c   Qin, Jianjun ^c   Li, Ke ^c   Liu, Ying ^c   Wang, Jiaxiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cell proliferation; Extracellular signal regulated kinase 1 2 (Erk1 2); MiR 136; Non small cell lung cancer (NSCLC); Serine threonine protein phosphatase 2A 55 kDa regulatory subunit B isoform(PPP2R2A)

Indexed keywords

MICRORNA; MICRORNA 136; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ANCHORAGE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; AGED; BASE PAIRING; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; RNA INTERFERENCE;

EID: 84894472515     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1087-2     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784-96.
3. Lagos-QuintanaM, Rauhut R, LendeckelW, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853-8.
4. Bartel DP.MicroRNAs: genomics, biogenesis,mechanism, and function. Cell. 2004;116:281-97.
5. Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272-86.
6. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-5.
7. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310:1817-21.
8. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-14.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-66.
10. Yu J, Wang F, Yang GH, et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun. 2006;349:59-68.
11. Liu SP, Fu RH, Yu HH, et al. MicroRNAs regulation modulated selfrenewal and lineage differentiation of stem cells. Cell Transplant. 2009;18:1039-45.
12. Yang Y,Wu J, Guan H, et al. MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett. 2012;586:3608-12.
13. Lee DY, Jeyapalan Z, Fang L, et al. Expression of versican 3'-untranslated region modulates endogenous microRNA functions. PLoS One. 2010;5:e13599.
14. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40.
15. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. CellMol Life Sci. 2008;65:3525-44.
16. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153-83.
17. Pages G, Milanini J, Richard DE, et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci. 2000;902:187-200.
18. Joslin EJ,Opresko LK,Wells A,Wiley HS, Lauffenburger DA. EGFreceptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci. 2007;120:3688-99.
19. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-54.
20. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.
21. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
22. Marks JL, Gong Y, Chitale D, et al. NovelMEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68:5524-8.
23. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-47.
24. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810-6.
25. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358-62.
26. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96:111-5.
27. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189-98.
28. Navarro A, Diaz T, Gallardo E, et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol. 2011;103:411-5.
29. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008;27:3845-55.
30. Skrzypski M, Dziadziuszko R, Jassem J. MicroRNA in lung cancer diagnostics and treatment. Mutat Res. 2011;717:25-31.
31. Mao X, Boyd LK, Yanez-Munoz RJ, et al. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res. 2011;1:604-17.
32. Jayadeva G, Kurimchak A, Garriga J, et al. B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastomarelated protein p107 and its activation. J Biol Chem. 2010;285:29863-73.
33. Alvarez-FernandezM, Halim VA, Aprelia M, Laoukili J, Mohammed S, Medema RH. Protein phosphatase 2A (B55alpha) prevents premature activation of forkhead transcription factor FoxM1 by antagonizing cyclin A/cyclin-dependent kinase-mediated phosphorylation. J Biol Chem. 2011;286:33029-36.
34. Yan L, Guo S, Brault M, et al. The B55alpha-containing PP2A holoenzyme dephosphorylates FOXO1 in islet beta-cells under oxidative stress. Biochem J. 2012;444:239-47.
35. Zhang W, Yang J, Liu Y, et al. PR55 alpha, a regulatory subunit of PP2A, specifically regulates PP2A-mediated beta-catenin dephosphorylation. J Biol Chem. 2009;284:22649-56.
36. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008;283:1882-92.
37. Strack S. Overexpression of the protein phosphatase 2A regulatory subunit Bgamma promotes neuronal differentiation by activating the MAP kinase (MAPK) cascade. J Biol Chem. 2002;277:41525-32.